Jaguar Health Inc (NASDAQ:JAGX)’s stock price fell 8.2% during mid-day trading on Wednesday . The stock traded as low as $1.41 and last traded at $1.46, 1,154,189 shares changed hands during trading. An increase of 150% from the average session volume of 460,815 shares. The stock had previously closed at $1.59.
JAGX has been the subject of several research analyst reports. HC Wainwright set a $10.00 price target on Jaguar Health and gave the company a “buy” rating in a report on Tuesday, July 2nd. LADENBURG THALM/SH SH initiated coverage on Jaguar Health in a report on Thursday, September 12th. They set a “buy” rating and a $5.00 price target for the company. ValuEngine upgraded Jaguar Health from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research cut Jaguar Health from a “buy” rating to a “hold” rating in a report on Thursday, August 15th.
The firm has a market cap of $63.28 million, a PE ratio of -0.01 and a beta of 0.74. The firm has a fifty day simple moving average of $1.31 and a two-hundred day simple moving average of $1.58. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.24 and a current ratio of 0.35.
About Jaguar Health (NASDAQ:JAGX)
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Recommended Story: Understanding each part of a balance sheet
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.